Quantum BioPharma Management
Management criteria checks 2/4
Quantum BioPharma's CEO is Zeeshan Saeed, appointed in Jul 2021, has a tenure of 3.08 years. total yearly compensation is $599.87K, comprised of 37.1% salary and 62.9% bonuses, including company stock and options. directly owns 2.65% of the company’s shares, worth CA$174.12K. The average tenure of the management team and the board of directors is 3.1 years and 2.9 years respectively.
Key information
Zeeshan Saeed
Chief executive officer
US$599.9k
Total compensation
CEO salary percentage | 37.1% |
CEO tenure | 3.1yrs |
CEO ownership | 2.7% |
Management average tenure | 3.1yrs |
Board average tenure | 2.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$7m |
Mar 31 2024 | n/a | n/a | -US$10m |
Dec 31 2023 | US$600k | US$223k | -US$18m |
Sep 30 2023 | n/a | n/a | -US$23m |
Jun 30 2023 | n/a | n/a | -US$29m |
Mar 31 2023 | n/a | n/a | -US$31m |
Dec 31 2022 | US$774k | US$239k | -US$27m |
Sep 30 2022 | n/a | n/a | -US$27m |
Jun 30 2022 | n/a | n/a | -US$25m |
Mar 31 2022 | n/a | n/a | -US$30m |
Dec 31 2021 | US$1m | US$225k | -US$34m |
Sep 30 2021 | n/a | n/a | -US$32m |
Jun 30 2021 | n/a | n/a | -US$39m |
Mar 31 2021 | n/a | n/a | -US$30m |
Dec 31 2020 | US$899k | US$212k | -US$28m |
Sep 30 2020 | n/a | n/a | -US$36m |
Jun 30 2020 | n/a | n/a | -US$35m |
Mar 31 2020 | n/a | n/a | -US$41m |
Dec 31 2019 | US$2m | US$249k | -US$34m |
Sep 30 2019 | n/a | n/a | -US$38m |
Jun 30 2019 | n/a | n/a | -US$25m |
Mar 31 2019 | n/a | n/a | -US$16m |
Dec 31 2018 | US$503k | US$183k | -US$17m |
Compensation vs Market: Zeeshan's total compensation ($USD599.87K) is above average for companies of similar size in the Canadian market ($USD176.07K).
Compensation vs Earnings: Zeeshan's compensation has been consistent with company performance over the past year.
CEO
Zeeshan Saeed (54 yo)
3.1yrs
Tenure
US$599,873
Compensation
Mr. Zeeshan Saeed serves as Executive Co-Chairman at FSD Pharma Inc. since May 24, 2018 and serves as its President since July 27, 2021 and Chief Executive Officer since June 29, 2023. He serves as Co-Chai...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 3.1yrs | US$599.87k | 2.65% $ 174.1k | |
Founder & Executive Co-Chairman | 6.2yrs | US$599.87k | 1.2% $ 79.0k | |
Chief Financial Officer | 3.3yrs | US$178.21k | 0% $ 0 | |
Chief Operating Officer | 3yrs | US$602.87k | 0% $ 0 | |
CEO of Lucid & Director | 2.9yrs | US$521.97k | 1.68% $ 110.5k | |
Corporate Secretary | no data | no data | no data | |
President of FSD BioSciences | 3.4yrs | no data | no data | |
Vice President of Clinical & Scientific Affairs of Lucid | no data | US$110.30k | 0% $ 0 | |
Vice President of Quality-Lucid | no data | US$144.82k | no data |
3.1yrs
Average Tenure
48yo
Average Age
Experienced Management: QNTM's management team is considered experienced (3.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Founder | 3.3yrs | US$599.87k | 2.65% $ 174.1k | |
Founder & Executive Co-Chairman | 6.2yrs | US$599.87k | 1.2% $ 79.0k | |
CEO of Lucid & Director | 1.8yrs | US$521.97k | 1.68% $ 110.5k | |
Member of Research & Clinical Advisory Board | 2.6yrs | no data | no data | |
Member of Research & Clinical Advisory Board | 2.8yrs | no data | no data | |
Member of Research & Clinical Advisory Board | 2.9yrs | no data | no data | |
Independent Director | 1.3yrs | no data | no data | |
Independent Director | 3.2yrs | US$139.37k | 0.14% $ 8.9k | |
Member of Research & Clinical Advisory Board | 2.9yrs | no data | no data | |
Member of Research & Clinical Advisory Board | 2.9yrs | no data | no data | |
Member of Research & Clinical Advisory Board | 2.9yrs | no data | no data | |
Member of Regulatory Advisory Board | 2.8yrs | no data | no data |
2.9yrs
Average Tenure
54yo
Average Age
Experienced Board: QNTM's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.